These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8306416)

  • 21. Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial.
    Hofheinz RD; Hartmann JT; Willer A; Oechsle K; Hartung G; Gnad U; Saussele S; Kreil S; Bokemeyer C; Hehlmann R; Hochhaus A
    Br J Cancer; 2004 Aug; 91(5):834-8. PubMed ID: 15238990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer.
    Ferrarotto R; Machado K; Mak MP; Shah N; Takahashi TK; Costa FP; Overman MJ; Kopetz S; Hoff PM
    Eur J Cancer; 2012 Apr; 48(6):820-6. PubMed ID: 22330318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.
    Lorvidhaya V; Chitapanarux I; Sangruchi S; Lertsanguansinchai P; Kongthanarat Y; Tangkaratt S; Visetsiri E
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1226-32. PubMed ID: 12654431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V; Giles FJ
    Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer.
    Propper DJ; Levitt NC; O'Byrne K; Braybrooke JP; Talbot DC; Ganesan TS; Thompson CH; Rajagopalan B; Littlewood TJ; Dixon RM; Harris AL
    Br J Cancer; 2000 Jun; 82(11):1776-82. PubMed ID: 10839290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases.
    Pernot S; Velut G; Kourie RH; Amouyal G; Sapoval M; Pointet AL; Landi B; Zaimi Y; Lepère C; Pellerin O; Taieb J
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):255-260. PubMed ID: 29233520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitomycin C and UFT/leucovorin as salvage treatment in patients with advanced colorectal cancer.
    Michalaki V; Gennatas S; Gennatas C
    J BUON; 2010; 15(2):270-3. PubMed ID: 20658720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I controlled trials of WR-2721 and cyclophosphamide.
    Glick JH; Glover D; Weiler C; Norfleet L; Yuhas J; Kligerman MM
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1777-80. PubMed ID: 6090370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma.
    Seitz JF; Perrier H; Giovannini M; Capodano G; Bernardini D; Bardou VJ
    J Chemother; 1998 Jun; 10(3):258-65. PubMed ID: 9669654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.
    Rao S; Cunningham D; Price T; Hill ME; Ross PJ; Tebbutt N; Norman AR; Oates J; Shellito P
    Br J Cancer; 2004 Aug; 91(5):839-43. PubMed ID: 15266319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
    Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
    Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Edmonson JH; Ryan LM; Blum RH; Brooks JS; Shiraki M; Frytak S; Parkinson DR
    J Clin Oncol; 1993 Jul; 11(7):1269-75. PubMed ID: 8315424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute].
    Zoetmulder FA; van der Vange N; Witkamp AJ; Kaag MM; Boot H; Beijnen JH
    Ned Tijdschr Geneeskd; 1999 Sep; 143(37):1863-8. PubMed ID: 10526600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma.
    Veeder MH; Jett JR; Su JQ; Mailliard JA; Foley JF; Dalton RJ; Etzell PS; Marschke RF; Kardinal CG; Maksymiuk AW
    Cancer; 1992 Nov; 70(9):2281-7. PubMed ID: 1394057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The chemoradiotherapy of advanced colorectal carcinoma--the results and toxicity in a pilot study with 44 patients].
    Brockmann WP; Wiegel T; Sommer K; Steiner P; Hübener KH
    Strahlenther Onkol; 1993 Feb; 169(2):107-13. PubMed ID: 8451725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
    Culy CR; Spencer CM
    Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer.
    Hansen RM; Ryan L; Anderson T; Krzywda B; Quebbeman E; Benson A; Haller DG; Tormey DC
    J Natl Cancer Inst; 1996 May; 88(10):668-74. PubMed ID: 8627643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.
    Rosati G; Rossi A; Germano D; Reggiardo G; Manzione L
    Anticancer Res; 2003; 23(3C):2981-5. PubMed ID: 12926149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitomycin C and lonidamine as second-line treatment of advanced colorectal cancer patients.
    Maiello E; Giotta F; Gebbia V; Testa A; Galetta D; Riccardi F; Gebbia N; Colucci G
    Anticancer Res; 1996; 16(5B):3177-9. PubMed ID: 8967732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
    Yamada Y; Shirao K; Hyodo I; Arai Y; Denda T; Ambo T; Ohtsu A
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):125-30. PubMed ID: 12783200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.